Gastrointestinal Stromal Tumors
"Gastrointestinal Stromal Tumors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
All tumors in the GASTROINTESTINAL TRACT arising from mesenchymal cells (MESODERM) except those of smooth muscle cells (LEIOMYOMA) or Schwann cells (SCHWANNOMA).
| Descriptor ID |
D046152
|
| MeSH Number(s) |
C04.557.450.565.370 C06.301.371.308 C06.405.249.308
|
| Concept/Terms |
Gastrointestinal Stromal Tumors- Gastrointestinal Stromal Tumors
- Stromal Tumor, Gastrointestinal
- Stromal Tumors, Gastrointestinal
- Tumor, Gastrointestinal Stromal
- Tumors, Gastrointestinal Stromal
- Gastrointestinal Stromal Neoplasms
- Neoplasm, Gastrointestinal Stromal
- Neoplasms, Gastrointestinal Stromal
- Stromal Neoplasm, Gastrointestinal
- Stromal Neoplasms, Gastrointestinal
- Gastrointestinal Stromal Tumor
- Gastrointestinal Stromal Neoplasm
|
Below are MeSH descriptors whose meaning is more general than "Gastrointestinal Stromal Tumors".
Below are MeSH descriptors whose meaning is more specific than "Gastrointestinal Stromal Tumors".
This graph shows the total number of publications written about "Gastrointestinal Stromal Tumors" by people in this website by year, and whether "Gastrointestinal Stromal Tumors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 2 | 0 | 2 |
| 2010 | 1 | 0 | 1 |
| 2016 | 3 | 0 | 3 |
| 2020 | 5 | 1 | 6 |
| 2021 | 10 | 0 | 10 |
| 2022 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Gastrointestinal Stromal Tumors" by people in Profiles.
-
Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study. Clin Cancer Res. 2022 04 14; 28(8):1672-1679.
-
KIT Exon 9-Mutated Gastrointestinal Stromal Tumours: Biology and Treatment. Chemotherapy. 2022; 67(2):81-90.
-
Oncological Outcome After Diagnostic Biopsies in Gastrointestinal Stromal Tumors: A Retrospective Cohort Study. Ann Surg. 2021 12 01; 274(6):e1093-e1098.
-
Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study. Clin Cancer Res. 2021 12 01; 27(23):6333-6342.
-
Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study. Oncologist. 2021 11; 26(11):e2053-e2060.
-
Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour. Eur J Cancer. 2021 09; 155:236-244.
-
Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study. J Clin Oncol. 2021 10 01; 39(28):3128-3139.
-
Fibroblast Growth Factor Receptor (FGFR) Signaling in GIST and Soft Tissue Sarcomas. Cells. 2021 06 17; 10(6).
-
Clinicopathological features and treatment outcome of oesophageal gastrointestinal stromal tumour (GIST): A large, retrospective multicenter European study. Eur J Surg Oncol. 2021 08; 47(8):2173-2181.
-
Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy. Oncologist. 2021 04; 26(4):e639-e649.